{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tazarotene+Cream%2C+0.1+%25",
    "query": {
      "intervention": "Tazarotene Cream, 0.1 %"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 15,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tazarotene+Cream%2C+0.1+%25&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T04:38:46.360Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00469755",
      "title": "Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Adapalene Gel, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Tazarotene Cream, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "12 Years to 35 Years"
      },
      "enrollment_count": 302,
      "start_date": "2006-02",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2022-07-29",
      "last_synced_at": "2026-10-01T04:38:46.360Z",
      "location_count": 12,
      "location_summary": "San Diego, California • Detroit, Michigan • Fridley, Minnesota + 9 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Fridley",
          "state": "Minnesota"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00469755"
    },
    {
      "nct_id": "NCT00713609",
      "title": "Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Benzoyl peroxide gel",
          "type": "DRUG"
        },
        {
          "name": "Clindamycin gel",
          "type": "DRUG"
        },
        {
          "name": "Tazarotene cream",
          "type": "DRUG"
        },
        {
          "name": "Vehicle gel",
          "type": "DRUG"
        },
        {
          "name": "Vehicle cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stiefel, a GSK Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 591,
      "start_date": "2008-06",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2017-03-06",
      "last_synced_at": "2026-10-01T04:38:46.360Z",
      "location_count": 16,
      "location_summary": "Little Rock, Arkansas • Fremont, California • Sacramento, California + 13 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00713609"
    },
    {
      "nct_id": "NCT02160678",
      "title": "Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Vehicle",
          "type": "DRUG"
        },
        {
          "name": "Tazarotene Cream, 0.1 %",
          "type": "DRUG"
        },
        {
          "name": "Tazorac Cream, 0.1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "G & W Laboratories Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 1741,
      "start_date": "2014-05",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-03",
      "last_synced_at": "2026-10-01T04:38:46.360Z",
      "location_count": 1,
      "location_summary": "Arlington Hts., Illinois",
      "locations": [
        {
          "city": "Arlington Hts.",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02160678"
    },
    {
      "nct_id": "NCT00783965",
      "title": "Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Skin Carcinoma"
      ],
      "interventions": [
        {
          "name": "tazarotene",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCSF Benioff Children's Hospital Oakland",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 34,
      "start_date": "2004-07",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2016-02-11",
      "last_synced_at": "2026-10-01T04:38:46.360Z",
      "location_count": 3,
      "location_summary": "Oakland, California • New York, New York",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00783965"
    },
    {
      "nct_id": "NCT00440024",
      "title": "The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sun-Damaged Skin",
        "Retinoid Intolerance"
      ],
      "interventions": [
        {
          "name": "Tazorac",
          "type": "DRUG"
        },
        {
          "name": "Dove Mild Cleanser",
          "type": "DRUG"
        },
        {
          "name": "Dove Facial Moisturizer",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 40,
      "start_date": "2007-02",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2020-03-13",
      "last_synced_at": "2026-10-01T04:38:46.360Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00440024"
    },
    {
      "nct_id": "NCT02886715",
      "title": "A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Tazarotene Cream 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Tazorac®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fougera Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 1110,
      "start_date": "2016-09-21",
      "completion_date": "2017-05-31",
      "has_results": true,
      "last_update_posted_date": "2018-08-17",
      "last_synced_at": "2026-10-01T04:38:46.360Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • Conway, Arkansas • Hot Springs, Arkansas + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Conway",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02886715"
    },
    {
      "nct_id": "NCT00834210",
      "title": "Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Dapsone",
          "type": "DRUG"
        },
        {
          "name": "Tazarotene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 171,
      "start_date": "2008-12",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2011-10-31",
      "last_synced_at": "2026-10-01T04:38:46.360Z",
      "location_count": 1,
      "location_summary": "Fremont, California",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00834210"
    },
    {
      "nct_id": "NCT03599193",
      "title": "A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Tazarotene Lotion, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Tazarotene Cream, 0.1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Reddy's Laboratories Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "9 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2017-10-04",
      "completion_date": "2018-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-03-01",
      "last_synced_at": "2026-10-01T04:38:46.360Z",
      "location_count": 2,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03599193"
    },
    {
      "nct_id": "NCT02218034",
      "title": "Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "AGN-190168 Formulation 1",
          "type": "DRUG"
        },
        {
          "name": "AGN-190168 Formulation 2",
          "type": "DRUG"
        },
        {
          "name": "tazarotene gel 0.1%",
          "type": "DRUG"
        },
        {
          "name": "tazarotene cream 0.1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2014-08",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-04-30",
      "last_synced_at": "2026-10-01T04:38:46.360Z",
      "location_count": 1,
      "location_summary": "College Station, Texas",
      "locations": [
        {
          "city": "College Station",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02218034"
    },
    {
      "nct_id": "NCT01616654",
      "title": "Dose Range Study of CD5789 in Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "CD5789 25 µg/g cream",
          "type": "DRUG"
        },
        {
          "name": "CD5789 50 µg/g cream",
          "type": "DRUG"
        },
        {
          "name": "CD5789 100 µg/g cream",
          "type": "DRUG"
        },
        {
          "name": "Tazarotene 0.1% gel",
          "type": "DRUG"
        },
        {
          "name": "Vehicle cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "12 Years to 35 Years"
      },
      "enrollment_count": 304,
      "start_date": "2012-06-20",
      "completion_date": "2014-06-12",
      "has_results": true,
      "last_update_posted_date": "2021-09-20",
      "last_synced_at": "2026-10-01T04:38:46.360Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Glendale, California • Marina del Rey, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Marina del Rey",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01616654"
    }
  ]
}